183TiP - Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

M Ignatiadis,M Brandao,M Maetens,N Ponde,S Martel,S Drisis,I Veys,S Mazy,E Bollue,P Neven,F.P Duhoux,J Chapiro,A.H Awada,T Besse-Hammer,M Paesmans,M Piccart,P Vuylsteke,C Sotiriou

doi:10.1093/annonc/mdy269.181

183TiP - Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

M Ignatiadis, M Brandao + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdy269.181

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2018
License type: publisher-specific-oa

Affiliation: Institut Jules Bordet, Hôpital Charles-Le Moyne, Clinique Saint-Joseph, Breast Center, Centre Hospitalier Sud Francilien, CHU Dinant Godinne UCL Namur

#Endocrine Therapy In Estrogen Receptor #Therapy In Estrogen Receptor + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

183TiP - Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Full Text